Janux Therapeutics (JANX) Expected to Announce Earnings on Wednesday

Key Points

• Janux Therapeutics is set to report its Q2 2025 earnings on August 6, with analysts forecasting an EPS of (-$0.50) and revenue of $0.30 million for the quarter.
• The company's stock is currently trading around $24.17 with a market cap of $1.43 billion, facing a 5.4% decline recently and a 52-week range between $22.48 and $71.71.
• Raymond James has initiated coverage on Janux Therapeutics with an "outperform" rating and a target price of $65.00, while the average rating among analysts stands at "Buy" with a consensus price target of $91.89.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Janux Therapeutics to post earnings of ($0.50) per share and revenue of $0.30 million for the quarter.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. On average, analysts expect Janux Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Janux Therapeutics Trading Down 1.9%

Shares of Janux Therapeutics stock traded down $0.45 on Friday, reaching $23.56. 601,583 shares of the company were exchanged, compared to its average volume of 800,036. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -17.32 and a beta of 2.86. Janux Therapeutics has a one year low of $22.48 and a one year high of $71.71. The company has a 50-day moving average of $24.74 and a 200 day moving average of $29.56.

Analysts Set New Price Targets

Separately, Raymond James Financial began coverage on Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 price target on the stock. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $91.89.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JANX. AQR Capital Management LLC grew its holdings in Janux Therapeutics by 71.7% in the 1st quarter. AQR Capital Management LLC now owns 9,717 shares of the company's stock valued at $262,000 after buying an additional 4,059 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Janux Therapeutics by 18.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company's stock valued at $583,000 after buying an additional 3,393 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Janux Therapeutics by 12.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company's stock worth $5,033,000 after purchasing an additional 20,657 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.